Affiliation:
1. Faculty of Life science and Technology Kunming University of Science and Technology Kunming People's Republic of China
2. Medical School Kunming University of Science and Technology Kunming People's Republic of China
3. Department of Pathology 920th Hospital of the Joint Logistics Support Force of PLA Kunming People's Republic of China
4. Department of Medical Administration The Third People's Hospital of Yunnan Province Kunming People's Republic of China
Abstract
AbstractCancer has become a prominent disease that seriously endangers human health. The complexity of the biological characteristics of the tumor makes it challenging for traditional therapeutic drugs to penetrate tumor tissues and exert their antitumor effects. Internalizing RGD peptide (iRGD) is a novel tumor‐homing peptide that binds to αvβ3 and αvβ5 integrins on the surface of tumor vessels through the C‐end rule (CendR) motif. The CendR motif binds to the neuropilin‐1 (NRP‐1) receptor on tumor cells, initiating NRP‐1‐mediated transcytosis to facilitate drug entry into the tumor tissue. Multiple studies demonstrated that iRGD improved the penetration and targeting of antitumor drugs, thereby enhancing their antitumor efficacy. In this review, we initially described the origins of iRGD and its penetration mechanism. Furthermore, we presented updates on the application of iRGD in cancer chemotherapy, photodynamic therapy, gene therapy, immunotherapy, treatment with antibodies or protein‐based biologics, and tumor imaging.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献